Effects of Ambroxol combined with Cefoperazone and Sulbactam in treatment of neonatal pneumonia
Objective:To observe effects of Ambroxol combined with Cefoperazone and Sulbactam in treatment of neonatal pneumonia(NP).Methods:The clinical data of 94 children with NP admitted to this hospital from August 2021 to January 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and observation group,47 cases in each.The control group was treated with Cefoperazone and Sulbactam,while the observation group was treated with Ambroxol on the basis of those of the control group.The clinical efficacy,the disappearance time of clinical symptoms(cough,shortness of breath,fever,cyanosis,lung rale),the levels of inflammatory factors[procalcitonin(PCT),C-reactive protein(CRP),intercellular adhesion molecule-1(ICAM-1),interleukin-6(IL-6)],the myocardial enzyme indexes[creatine kinase(CK),creatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH)]levels before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.62%(44/47),which was higher than 76.60%(36/47)of the control group,and the difference was statistically significant(P<0.05).The disappearance time of clinical symptoms such as cough,shortness of breath,fever,cyanosis and lung rale in the observation group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of PCT,CRP,ICAM-1 and IL-6 in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of CK,CK-MB and LDH in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Ambroxol combined with Cefoperazone and Sulbactam in the treatment of the children with NP can improve the clinical efficacy,promote the recovery of clinical symptoms,and reduce the body's inflammatory response and the myocardial injury.Moreover,it is superior to single Cefoperazone and Sulbactam treatment.
Cefoperazone and SulbactamAmbroxolNeonatal pneumoniaInflammatory factorMyocardial enzymeAdverse reaction
NETL
NSTL
万方数据
